Comparative analysis of the immunogenicity of SARS-CoV nucleocapsid DNA vaccine administrated with different routes in mouse model (Q44183717)

30 November 2017

Comparative analysis of the immunogenicity of SARS-CoV nucleocapsid DNA vaccine administrated with different routes in mouse model (English)

1 reference

30 November 2017

0 references

1 reference

1 reference

Hui Hu

1

1 reference

30 November 2017

Xianqing Huang

2

1 reference

30 November 2017

Ling Tao

3

1 reference

30 November 2017

Yi Huang

4

1 reference

30 November 2017

Bao-An Cui

5

1 reference

30 November 2017

Hanzhong Wang

6

1 reference

30 November 2017

language of work or name

English

0 references

publication date

30 January 2009

1 reference

30 November 2017

6

1 reference

based on heuristic

inferred from page(s)

published in

Vaccine

1 reference

30 November 2017

27

1 reference

30 November 2017

11

1 reference

30 November 2017

1758-1763

1 reference

SARS--beginning to understand a new virus

30 November 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.021

Aetiology: Koch's postulates fulfilled for SARS virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.021

A novel coronavirus associated with severe acute respiratory syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.021

Identification of a novel coronavirus in patients with severe acute respiratory syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.021

Coronavirus as a possible cause of severe acute respiratory syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.021

The Genome sequence of the SARS-associated coronavirus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.021

Characterization of a novel coronavirus associated with severe acute respiratory syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.021

Severe Acute Respiratory Syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.021

DNA mediated immunization with encoding the nucleoprotein gene of porcine transmissible gastroenteritis virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.021

Nucleocapsid-independent specific viral RNA packaging via viral envelope protein and viral RNA signal.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.021

Genetic evidence for a structural interaction between the carboxy termini of the membrane and nucleocapsid proteins of mouse hepatitis virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.021

Sequence comparison of the N genes of five strains of the coronavirus mouse hepatitis virus suggests a three domain structure for the nucleocapsid protein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.021

Vaccine efficacy of a cell lysate with recombinant baculovirus-expressed feline infectious peritonitis (FIP) virus nucleocapsid protein against progression of FIP.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.021

Cooperation between transmissible gastroenteritis coronavirus (TGEV) structural proteins in the in vitro induction of virus-specific antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.021

Antibody detection of SARS-CoV spike and nucleocapsid protein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.021

Antigenicity analysis of different regions of the severe acute respiratory syndrome coronavirus nucleocapsid protein.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.021

Evaluation of antibody responses against SARS coronaviral nucleocapsid or spike proteins by immunoblotting or ELISA.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.021

Induction of SARS-nucleoprotein-specific immune response by use of DNA vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.021

Profiles of antibody responses against severe acute respiratory syndrome coronavirus recombinant proteins and their potential use as diagnostic markers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.021

Cloning, sequencing, expression, and purification of SARS-associated coronavirus nucleocapsid protein for serodiagnosis of SARS.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.021

Immune responses with DNA vaccines encoded different gene fragments of severe acute respiratory syndrome coronavirus in BALB/c mice.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.021

Effects of a SARS-associated coronavirus vaccine in monkeys.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.021

Generation and characterization of DNA vaccines targeting the nucleocapsid protein of severe acute respiratory syndrome coronavirus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.021

Induction of Th1 type response by DNA vaccinations with N, M, and E genes against SARS-CoV in mice.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.021

The development of vaccines against SARS corona virus in mice and SCID-PBL/hu mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.021

Synergistic DNA-MVA prime-boost vaccination regimes for malaria and tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.021

A review of vaccine research and development: the human immunodeficiency virus (HIV).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.021

Markedly enhanced immunogenicity of a Pfs25 DNA-based malaria transmission-blocking vaccine by in vivo electroporation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.021

In vivo electroporation improves immune responses to DNA vaccination in sheep.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.021

Live oral Salmonella vaccines: potential use of attenuated strains as carriers of heterologous antigens to the immune system

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.021

Attenuated Salmonella typhimurium SL3261 as a vaccine vector for recombinant antigen in rabbits.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.021

Oral transgene vaccination mediated by attenuated Salmonellae is an effective method to prevent Herpes simplex virus-2 induced disease in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.021

Oral delivery of DNA vaccines using attenuated Salmonella typhimurium as carrier.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.021

Correlates of protection induced by live Aro- Salmonella typhimurium vaccines in the murine typhoid model.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.021

Standardisation and quality assurance of lymphocyte proliferation assays for use in the assessment of immune function. European Concerted Action on Immunological and Virological Markers of HIV Disease Progression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.021

Efficacy of DNA vaccination by different routes of immunisation in sheep.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.021

Induction of specific immune responses by severe acute respiratory syndrome coronavirus spike DNA vaccine with or without interleukin-2 immunization using different vaccination routes in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.021

Potent immunogenicity of an HIV-1 gag-pol fusion DNA vaccine delivered by in vivo electroporation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.021

Increased DNA vaccine delivery and immunogenicity by electroporation in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.021

Enhancement of DNA vaccine potency in rhesus macaques by electroporation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.021

An autologous oral DNA vaccine protects against murine melanoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.021

Unique immunogenicity of hepatitis B virus DNA vaccine presented by live-attenuated Salmonella typhimurium.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.021

Mucosal and systemic HIV-1 Env-specific CD8(+) T-cells develop after intragastric vaccination with a Salmonella Env DNA vaccine vector.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.021

The nature of the attenuation of Salmonella typhimurium strains expressing human papillomavirus type 16 virus-like particles determines the systemic and mucosal antibody responses in nasally immunized mice.

7 January 2021

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/19186202

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1016/J.VACCINE.2009.01.021

1 reference

30 November 2017

1 reference